<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563366</url>
  </required_header>
  <id_info>
    <org_study_id>MSCs-KTx-DCD-150925</org_study_id>
    <nct_id>NCT02563366</nct_id>
  </id_info>
  <brief_title>Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant.</brief_title>
  <official_title>Effect of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Recovery of Poor Early Graft Function Post Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <brief_summary>
    <textblock>
      This study is designed to investigate whether allogeneic bone marrow-derived mesenchymal stem
      cells (BM-MSCs) can promote function recovery in patients with poor early graft function
      after kidney transplantation from Chinese Donation after Citizen Death (DCD). DCD kidney
      transplant recipients with poor early graft function (with or without dialysis) post
      transplant are equally randomized into MSCs group or control group. Patients in MSCs group
      are administered MSCs treatment. Allogeneic BM-MSCs (1*10^6/kg) from third party are given
      intravenously for four consecutive doses every week after enrollment. Patients in control
      group receive placebo. Renal allograft function (eGFR), rejection, patient/graft survival and
      severe adverse events up to 12 months post enrollment are monitored.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated glomerular filtration rate</measure>
    <time_frame>1 month</time_frame>
    <description>eGFR at one month post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate</measure>
    <time_frame>12 months</time_frame>
    <description>eGFR up to 12 months post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of normal renal function recovery</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to renal function recovery (days)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute rejection rate</measure>
    <time_frame>12 months</time_frame>
    <description>Acute rejection rate according to Banff 2013 criteria up to 12 months post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient and graft survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>patient and graft survival rate up to 12 months post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of severe adverse events up to 12 months post transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Acute Kidney Tubular Necrosis</condition>
  <arm_group>
    <arm_group_label>MSCs group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with early poor graft function receive allogeneic BM-MSCs at the dose of 1*10^6/kg every week for four consecutive doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with early poor graft function receive placebo of MSCs, i.e. saline every week for four consecutive doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BM-MSCs</intervention_name>
    <description>BM-MSCs are from third-party healthy volunteer donors.</description>
    <arm_group_label>MSCs group</arm_group_label>
    <other_name>allogeneic bone marrow-derived MSCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline is the placebo of MSCs in this study.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary kidney transplantation

          -  Kidneys are from donation after Chinese citizen death

          -  Poor early graft function with or without dialysis after transplantation

          -  Patient is willing and capable of giving written informed consent for study
             participation and able to participate in the study for 12 months

        Exclusion Criteria:

          -  Secondary kidney transplantation

          -  Combined or multi-organ transplantation

          -  Women who are pregnant, intend to become pregnant in the next 1 years, breastfeeding,
             or have a positive pregnancy test on enrollment or prior to study medication
             administration

          -  Panel reactive antibody (PRA)&gt;20% or CDC crossmatch is positive

          -  Donors or recipients are known hepatitis C antibody-positive or polymerase chain
             reaction (PCR) positive for hepatitis C

          -  Donors or recipients are known hepatitis B surface antigen-positive or PCR positive
             for hepatitis B

          -  Donors or recipients are known human immunodeficiency virus (HIV) infection

          -  Patients with active infection

          -  Recipients with a history of substance abuse (drugs or alcohol) within the past 6
             months, or psychotic disorders that are not capable with adequate study follow- up.

          -  Patients with severe cardiovascular dysfunction

          -  WBC&lt;3*10^9/L or RBC &lt;5g/dL

          -  Highly allergic constitution or having severe history of allergies.

          -  Patients with active peptic ulcer disease, chronic diarrhea, or gastrointestinal
             problem affect absorption

          -  Patients with a history of cancer within the last 5 years

          -  Prisoner or patients compulsorily detained (involuntarily incarcerated) for treatment
             or either a psychiatric or physical (e.g. infectious disease) illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changxi Wang, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changxi Wang, M.D., Ph.D</last_name>
    <phone>86-20-87333428</phone>
    <email>wangchx@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Longshan Liu, M.D., Ph.D</last_name>
    <phone>86-20-87306082</phone>
    <email>liulshan@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Changxi Wang, M.D., Ph.D</last_name>
      <phone>86-20-87333428</phone>
      <email>wangchx@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Longshan Liu, M.D., Ph.D</last_name>
      <phone>86-20-87306082</phone>
      <email>liulshan@mail.sysu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Changxi Wang, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23263506</url>
    <description>Previous publication</description>
  </link>
  <reference>
    <citation>Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W, Li X, Chen Z, Ma J, Liao D, Li G, Fang J, Pan G, Xiang AP. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013 Jan 15;95(1):161-8. doi: 10.1097/TP.0b013e3182754c53. Erratum in: Transplantation. 2014 Mar 27;97(6):e37. Pan, Guanghui [added].</citation>
    <PMID>23263506</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Changxi Wang</investigator_full_name>
    <investigator_title>Director of Organ Transplant Center</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>mesenchymal stem cell therapy</keyword>
  <keyword>poor early graft function</keyword>
  <keyword>delayed graft function</keyword>
  <keyword>ischemia reperfusion injury</keyword>
  <keyword>donation after cardiac death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Kidney Tubular Necrosis, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

